Short answer
Alector, Inc. (ALEC) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Alector announced financial results for the quarter ended September 30, 2026.
Alector, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Alector announced financial results for the quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed earnings release and financial performance data
Item EX-99.1 · Exhibit EX-99.1
- Q3 collaboration revenue $162.9M versus $3.3M, largely one-time recognition of deferred GSK revenue after termination
- Net income $124.6M, or $1.11 per share, versus $34.7M loss, masking underlying biotech operating performance
- Genentech license delivers $100M upfront, up to $1.17B milestones and tiered royalties for AL050
- $75.0M stock offering at $2.05 per share, 36.6M shares, strengthening funding but creating dilution
- Cash $138.7M before license and offering proceeds, extending projected runway into the second half of 2029
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alector, Inc. 8-K filings
Get the next ALEC 8-K as it lands
Follow ALEC for push alerts, or ask the research agent what this filing means.